# Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-22-023-ancillary-studies-to-the-niddk-inflammatory-bowel-disease/  
Official notice: https://www.grants.gov/search-results-detail/345103

> National Institutes of Health offered grants of up to $300,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 8, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-22-023 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | November 8, 2023 |
| Award ceiling | $300,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified over 250 susceptibility loci for IBD. The IBDGC has recently been renewed with a continued mission to characterize the genetic architecture of IBD phenotypes in diverse populations and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology and clinical course. However, current resources permit functional investigation of only a limited number of loci, genes and physiological domains, while the biological mechanisms underlying most of the identified IBD risk loci remain unknown. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of IBD susceptibility loci, causal variants and effector genes, and IBD-related phenotypes and physiological domains under investigation via Ancillary Studies utilizing the extensive resources including subjects, samples and datasets established by the IBDGC. Proposed Ancillary Studies should focus on causal variant identification and/or functional characterization of effector genes within IBD risk loci and must not duplicate studies either ongoing or already completed by the IBDGC.

## Questions people ask

### Is RFA-DK-22-023 still open?

No. It closed on November 8, 2023.

### Who can apply for Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed)?

Closed November 8, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $300,000 each.

### Who has been funded under RFA-DK-22-023?

NIH RePORTER lists 8 projects funded under RFA-DK-22-023 in fiscal 2024 to 2026, at 8 institutions. The most were at University of Pittsburgh at Pittsburgh, Stanford University, Sinai Health System.

### Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.